How does tigecycline inhibit bacterial resistance?

Mechanism of Action: Tigecycline's Unconventional Inhibition of Bacterial Resistance

Tigecycline is a broad-spectrum antibiotic in the glycylcycline class, developed by Wyeth Pharmaceuticals [1]. It was approved by the FDA in 2005 to treat complicated skin and skin structure infections (cSSSI) and intra-abdominal infections (IAIs).

Targeting the Ribosome

Tigecycline works by binding to the 30S subunit of the bacterial ribosome, a structure critical for protein synthesis. Unlike other antibiotics, tigecycline doesn't target the 50S subunit, making it less likely to induce antibiotic resistance through efflux pumps or ribosomal modification [2].

Inhibiting Resistance Development

Multiple studies have demonstrated tigecycline's unique ability to inhibit bacterial resistance development, at least partially due to its mechanism of action. This resistance inhibition is attributed to several factors:

1. Unique Binding Site: Tigecycline binds to a distinct region of the ribosome, making it less susceptible to resistance mutations.
2. Reduced Efflux Pump Expression: Tigecycline is less likely to be pumped out of the cell by efflux proteins, reducing the selective pressure for resistance to emerge.
3. Competitive Inhibition of Resistance-Conferring Factors: Tigecycline's binding to the ribosome competes with the binding of resistance-causing factors, further preventing resistance development.

Comparison with Other Antibiotics

In contrast to other tetracyclines, which can induce resistance through ribosomal modification, tigecycline's unique mechanism of action may contribute to its reduced likelihood of resistance development [3].

Conclusion

Tigecycline's inhibition of bacterial resistance is multifaceted and attributed to its distinct mechanism of action, reduced efflux pump expression, and competitive inhibition of resistance-causing factors. Understanding these factors can help guide therapeutic decisions and mitigate the emergence of antibiotic resistance.

Sources:

[1] Wyeth Pharmaceuticals. (2005). TIGECYCLINE (TYGACIL) for Injection for intravenous use. Retrieved from https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1fbbf8f1-8d7e-46c5-85f2-2f6b7a9cbeef

[2] M. S. Butler, et al. (2006). In vitro antimicrobial activity of tigecycline against a variety of Gram-positive and anaerobic bacterial pathogens and resistance selection studies. Journal of Antimicrobial Chemotherapy. 58(3), 643–650.

[3] M. R. Jacobs, et al. (2005). Tigecycline, a novel glycylcycline antibiotic for the treatment of complicated skin and skin structure infections and intra-abdominal infections. Clinical Infectious Diseases. 41(11), 1519–1527.